Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biomea Fusion, Inc. - Common Stock (NQ:BMEA)

1.360 +0.030 (+2.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biomea Fusion, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
SAIC Reports Q3 Results, Joins Uber, Wallbox And Other Big Stocks Moving Higher On Monday
U.S. stocks traded lower, with the Dow Jones index falling more than 100 points on Monday. 
Via Benzinga
Topics Stocks
Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Patterson Companies, Inc. (NASDAQ: PDCO) moved lower during Wednesday’s session after the company reported worse-than-expected second-quarter financial results and lowered FY24 adjusted EPS... 
Via Benzinga
14 Analysts Have This to Say About Biomea Fusion
 
Via Benzinga
Why Biomea Fusion Stock Is Falling Today?
Biomea Fusion Inc (NASDAQ: BMEA) released preliminary topline data from its ongoing Phase 1 COVALENT-101 trial, showcasing initial responses in relapsed/refractory AML patients with  
Via Benzinga
What 18 Analyst Ratings Have To Say About Biomea Fusion
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Why Workday Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Shares of Workday, Inc. (NASDAQ: WDAY) surged in pre-market trading after the company reported upbeat earnings results for its third quarter. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes 
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure diabetes 
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 2 diabetes 
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes
BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1 diabetes 
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
 
Via Benzinga
Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest. 
Via Benzinga
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
From Biomea Fusion, Inc.
Via GlobeNewswire
Are (More) Big Gains Ahead for This Small Cap Biotech Stock?
With Biomea Fusion's share price nearly halved recently, oversold conditions seem to be setting in. This could be an opportunity for small cap growth investors. 
Via MarketBeat
Topics Initial Public Offering
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Dow Surges Over 50 Points; Avalo Therapeutics Shares Plummet
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining more than 50 points on Monday. The Dow traded up 0.18% to 33,788.05 while the NASDAQ fell 0.61% to 13,410.63. The S&P 500,... 
Via Benzinga
Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular... 
Via Benzinga
Crude Oil Rises; Carnival Shares Drop After Q2 Results
U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 80 points on Monday. The Dow traded down 0.02% to 33,719.54 while the NASDAQ fell 0.53% to 13,420.67. The S&P 500, also... 
Via Benzinga
Biomea Fusion Stock Is Trading Higher Today - Here's Why
Biomea Fusion Inc (NASDAQ: BMEA) announced the presentation of new clinical data from the first two cohorts from the Phase 2 portion of its ongoing Phase 1/2 clinical study (COVALENT-111) of BMF-219... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the week right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3
From Biomea Fusion, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.